PLA2G7
Basic information
Region (hg38): 6:46704201-46735693
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Platelet-activating factor acetylhydrolase deficiency | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Pulmonary | 3198761; 8675689; 10194471; 10733466 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PLA2G7 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 26 | 36 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 0 | |||||
non coding | 3 | |||||
Total | 0 | 2 | 31 | 11 | 6 |
Variants in PLA2G7
This is a list of pathogenic ClinVar variants found in the PLA2G7 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-46704602-G-A | Likely benign (Aug 28, 2018) | |||
6-46704609-T-C | not specified | Uncertain significance (Sep 19, 2023) | ||
6-46704657-T-C | not specified | Uncertain significance (Jan 26, 2022) | ||
6-46704715-TAATC-T | Benign (Aug 19, 2020) | |||
6-46705206-A-G | RECLASSIFIED - POLYMORPHISM • PLA2G7-related disorder | Benign (Dec 11, 2018) | ||
6-46705240-T-C | not specified | Uncertain significance (Apr 04, 2024) | ||
6-46705275-T-C | not specified | Uncertain significance (Feb 13, 2024) | ||
6-46705276-C-A | not specified | Uncertain significance (Jul 12, 2023) | ||
6-46705318-C-T | not specified | Likely benign (Mar 07, 2024) | ||
6-46708156-C-A | not specified | Uncertain significance (Aug 22, 2023) | ||
6-46708163-T-C | Platelet-activating factor acetylhydrolase deficiency | Uncertain significance (Mar 18, 2016) | ||
6-46709361-C-A | Platelet-activating factor acetylhydrolase deficiency • PLA2G7-related disorder | Benign (Feb 24, 2020) | ||
6-46709399-T-C | not specified | Uncertain significance (Dec 02, 2022) | ||
6-46709402-T-C | not specified | Uncertain significance (Aug 08, 2023) | ||
6-46709409-C-T | not specified | Uncertain significance (Aug 30, 2021) | ||
6-46710529-A-G | Platelet-activating factor acetylhydrolase deficiency | Uncertain significance (Apr 04, 2024) | ||
6-46710548-C-T | not specified | Likely benign (Oct 17, 2023) | ||
6-46710626-A-G | Likely benign (Feb 08, 2018) | |||
6-46710636-C-T | not specified | Uncertain significance (Aug 02, 2021) | ||
6-46710640-C-CTT | Platelet-activating factor acetylhydrolase deficiency | Uncertain significance (Mar 05, 2018) | ||
6-46710645-G-C | not specified | Uncertain significance (Nov 06, 2023) | ||
6-46710654-C-T | not specified | Likely benign (Mar 07, 2024) | ||
6-46710655-G-A | not specified | Uncertain significance (Nov 17, 2023) | ||
6-46711495-C-T | Platelet-activating factor acetylhydrolase deficiency • not specified | Uncertain significance (May 01, 2022) | ||
6-46711525-C-T | not specified | Uncertain significance (Dec 28, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PLA2G7 | protein_coding | protein_coding | ENST00000274793 | 11 | 31493 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
5.33e-22 | 0.000104 | 125330 | 3 | 410 | 125743 | 0.00164 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.05 | 274 | 229 | 1.20 | 0.0000108 | 2919 |
Missense in Polyphen | 108 | 87.815 | 1.2299 | 1148 | ||
Synonymous | -0.141 | 78 | 76.4 | 1.02 | 0.00000359 | 805 |
Loss of Function | -1.17 | 29 | 23.0 | 1.26 | 0.00000107 | 280 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00201 | 0.00201 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000381 | 0.000381 |
Finnish | 0.000186 | 0.000185 |
European (Non-Finnish) | 0.000829 | 0.000827 |
Middle Eastern | 0.000381 | 0.000381 |
South Asian | 0.00800 | 0.00794 |
Other | 0.00131 | 0.00130 |
dbNSFP
Source:
- Function
- FUNCTION: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.;
- Disease
- DISEASE: Asthma (ASTHMA) [MIM:600807]: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi. {ECO:0000269|PubMed:10733466}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Atopic hypersensitivity (ATOPY) [MIM:147050]: A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. {ECO:0000269|PubMed:10733466}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;
- Pathway
- Ether lipid metabolism - Homo sapiens (human);IL1 and megakaryocytes in obesity;Peptide hormone metabolism;Synthesis, secretion, and deacylation of Ghrelin;Metabolism of proteins;Glycerophospholipid metabolism;Lissencephaly gene (LIS1) in neuronal migration and development
(Consensus)
Recessive Scores
- pRec
- 0.304
Intolerance Scores
- loftool
- 1.00
- rvis_EVS
- 0.58
- rvis_percentile_EVS
- 82.25
Haploinsufficiency Scores
- pHI
- 0.0609
- hipred
- N
- hipred_score
- 0.207
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0145
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pla2g7
- Phenotype
- immune system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- lipid catabolic process;low-density lipoprotein particle remodeling;lipid oxidation;plasma lipoprotein particle oxidation;platelet activating factor metabolic process;positive regulation of inflammatory response;positive regulation of monocyte chemotaxis
- Cellular component
- extracellular region;cytoplasm;low-density lipoprotein particle
- Molecular function
- 1-alkyl-2-acetylglycerophosphocholine esterase activity;phospholipid binding;hydrolase activity, acting on ester bonds;calcium-independent phospholipase A2 activity